Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
FLUIDDA nv
Age
30–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female patient ≥ 30 years old
Patient with BMI ≥ 20
Written informed consent obtained
Female patient of childbearing potential who confirm that a contraception method was used at least 14 days before visit 1 and will continue to use a contraception method during the study.
Patient should be treated according to GOLD guidelines
COPD patient with GOLD stages III until IV
Patient with smoking history of at least 10 pack-years
Patient takes Spiriva® and a fixed combination of inhaled steroids and long acting beta agonist (LABA) at least 6 weeks before visit 1
Patient must be able to understand and complete the protocol requirements, instructions, questionnaires and protocol-stated restrictions.
You may not be if
Pregnant or lactating females
Patient with severe immunological diseases and/ or severe acute infectious diseases.
Patient with heart failure
Patient with diagnosis of cancer (except basal cell carcinoma)
Patient with a history of depression associated with suicidal ideation or behaviour
Patient with moderate or severe hepatic impairment.
Patient with lactose intolerance
Patient is unlikely to comply with the protocol or unable to understand the nature, scope and possible consequences of the study.
Patient who received any investigational new drug within the last 4 weeks prior to the screening visit or twice the duration of the biological effect of any drug (whichever is longer).
Clareo Health | Evaluation With CT Scan of Possible Changes in Airways After Treatment With Daxas® in Severe Chronic Obstructive Pulmonary Disease Patients
